Altimmune (ALT) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Altimmune (ALT) over the last 9 years, with Q3 2025 value amounting to -$0.21.
- Altimmune's EPS (Weighted Average and Diluted) rose 3437.5% to -$0.21 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.07, marking a year-over-year increase of 3184.71%. This contributed to the annual value of -$1.34 for FY2024, which is 1936.1% up from last year.
- Latest data reveals that Altimmune reported EPS (Weighted Average and Diluted) of -$0.21 as of Q3 2025, which was up 3437.5% from -$0.27 recorded in Q2 2025.
- Altimmune's 5-year EPS (Weighted Average and Diluted) high stood at -$0.21 for Q3 2025, and its period low was -$0.81 during Q3 2021.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.39 (2023), whereas its average is -$0.42.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first plummeted by 5000.0% in 2021, then surged by 4478.16% in 2024.
- Quarter analysis of 5 years shows Altimmune's EPS (Weighted Average and Diluted) stood at -$0.58 in 2021, then grew by 20.23% to -$0.46 in 2022, then fell by 28.74% to -$0.59 in 2023, then surged by 44.78% to -$0.33 in 2024, then skyrocketed by 36.0% to -$0.21 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.21 for Q3 2025, versus -$0.27 for Q2 2025 and -$0.26 for Q1 2025.